NCT03348514 - Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 15, 2018

Primary Completion Date

May 31, 2020

Study Completion Date

May 31, 2020

Conditions

Advanced Solid Tumors

Interventions

DRUG

CPX-POM - 30 mg/m^2

CPX-POM

DRUG

CPX-POM - 60 mg/m^2

CPX-POM

DRUG

CPX-POM - 120 mg/m^2

CPX-POM

DRUG

CPX-POM - 240 mg/m^2

CPX-POM

DRUG

CPX-POM - 360 mg/m^2

CPX-POM

DRUG

CPX-POM - 600 mg/m^2

CPX-POM

DRUG

CPX-POM - 900 mg/m^2

CPX-POM

DRUG

CPX-POM - 1200 mg/m^2

CPX-POM

Trial Locations (5)

Florida Cancer Specialists & Research Institute, Sarasota

Tennessee Oncology PLLC, Nashville

University of Kansas Medical Center, Kansas City

Stephenson Cancer Center, Oklahoma City

Sarah Cannon Research Institute, Denver